CRL vs. ELAN: Charles River Laboratories vs. Elanco Animal Health Stock Comparison
How do Charles River Laboratories (CRL) and Elanco Animal Health (ELAN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Charles River Laboratories (CRL) and Elanco Animal Health (ELAN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while ELAN is classified in Pharmaceuticals.
| Profile Item | CRL | ELAN |
|---|---|---|
| Name | Charles River Laboratories International, Inc. | Elanco Animal Health Incorporated |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 16.17 billion USD | 12.86 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 23, 2000 | September 20, 2018 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | CRL | ELAN |
|---|---|---|
| Total Return (1Y) | 110.83% | 24.03% |
| Total Return (3Y, Annualized) | 27.87% | 37.47% |
| Total Return (5Y, Annualized) | -1.57% | -4.24% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | CRL | ELAN |
|---|---|---|
| Volatility (1Y, Annualized) | 47.81% | 43.57% |
| Beta (5Y) | 1.33 | 1.65 |
| Max Drawdown (5Y) | -74.73% | -75.59% |
| Avg. Volume (3M) | 1.05M | 5.65M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | CRL | ELAN |
|---|---|---|
| Sharpe Ratio (1Y) | 2.23 | 0.45 |
| Sortino Ratio (1Y) | 3.58 | 0.66 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Charles River Laboratories (CRL) earns 1.27% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.27%
- Max
- 109.18%
- Q3
- 6.23%
- CRL
- 1.27%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ELAN
- --
Net Margin (TTM)
Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Charles River Laboratories (CRL) reports 1.01%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01%
- Max
- 18.05%
- Q3
- 4.78%
- CRL
- 1.01%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.86%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- ELAN
- -2.86%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Charles River Laboratories (CRL) at 23.42% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.42%
- Max
- 83.12%
- CRL
- 23.42%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64%
- Max
- 83.12%
- Q3
- 14.77%
- ELAN
- 6.64%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | CRL | ELAN |
|---|---|---|
| ROE (TTM) | 1.27% | -- |
| ROA (TTM) | 4.74% | -- |
| Net Margin (TTM) | 1.01% | -2.86% |
| Operating Margin (TTM) | 23.42% | 6.64% |
| Gross Margin (TTM) | 35.10% | 56.18% |
Growth
Revenue Growth
Elanco Animal Health (ELAN) at 6.22% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Neither side shows strong earnings momentum: Elanco Animal Health (ELAN) at -169.12% sits in the bottom EPS growth quartile, and Charles River Laboratories (CRL) at -1,555.00% is weaker still, below its industry range.
Growth Metrics
| Metric | CRL | ELAN |
|---|---|---|
| Revenue Growth (YoY) | -0.85% | 6.22% |
| Revenue Growth (3Y CAGR) | 0.33% | 2.25% |
| EPS Growth (YoY) | -1,555.00% | -169.12% |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Charles River Laboratories (CRL) shows current ratio of 1.41 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.41
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- CRL
- 1.41
- Min
- 0.10
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ELAN
- --
Debt / Equity (MRQ)
Elanco Animal Health (ELAN) at 0.64 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 1.42
- CRL
- 0.87
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.64
- Max
- 1.42
- Q3
- 0.65
- ELAN
- 0.64
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | CRL | ELAN |
|---|---|---|
| Current Ratio (MRQ) | 1.41 | -- |
| Debt / Equity (MRQ) | 0.87 | 0.64 |
| Net Debt / EBITDA | 2.92 | 3.49 |
Dividends
Dividend Yield (TTM)
Neither Charles River Laboratories (CRL) nor Elanco Animal Health (ELAN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Charles River Laboratories (CRL) nor Elanco Animal Health (ELAN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | CRL | ELAN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
366.87
- CRL
- 366.87
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ELAN
- --
P/S Ratio (TTM)
Elanco Animal Health (ELAN) at 2.50 sits in the cheaper P/S ratio quartile while Charles River Laboratories (CRL) at 4.07 prices around its industry’s middle — ELAN costs less per dollar of sales, though read it alongside growth and margins.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.07
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- CRL
- 4.07
- Q1
- 3.01
- Min
- 0.01
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ELAN
- 2.50
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Charles River Laboratories (CRL) at 5.01 and Elanco Animal Health (ELAN) at 1.95 are valued close to their industries’ norm against book — neither stands out from peers.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.01
- Max
- 13.53
- Q3
- 6.54
- CRL
- 5.01
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- ELAN
- 1.95
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | CRL | ELAN |
|---|---|---|
| P/E Ratio (TTM) | 366.87 | -- |
| P/S Ratio (TTM) | 4.07 | 2.50 |
| P/B Ratio (MRQ) | 5.01 | 1.95 |
| Free Cash Flow Yield (TTM) | 2.74% | -- |